Adalimumab treatment in adult patients with refractory non-infectious uveitis

Ebru Esen; Püren Işık; Selçuk Sızmaz; Nihal Demircan

Makale detayları

Adalimumab treatment in adult patients with refractory non-infectious uveitis

Yazarlar:

Ebru Esen | Püren Işık | Selçuk Sızmaz | Nihal Demircan

Yayıncı:

Cukurova University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Cukurova Medical Journal Vol.48 Issue 2, pp.457-462

Belge Tipi:

Makale

Yayın Tarihi:

2/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001286346

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: To assess the efficacy of adalimumab treatment in patients with refractory non-infectious uveitis. Materials and Methods: A retrospective analysis was carried out on patients with chronic non-infectious uveitis treated with adalimumab for longer than 12 months. All patients had active intraocular inflammation and were nonresponsive to other immunosuppressive agents before initiating adalimumab treatment. Results: Twenty-one patients 39 eyes were treated with adalimumab for a mean duration of 26.2  13.2 months. Eleven patients 52.4 remained relapse-free during the treatment. In only one patient 4.8 adalimumab was switched to another drug due to insufficient response. Adalimumab treatment was discontinued in five patients 23.8 after an attack-free period of at least 18 months. Conclusion: Adalimumab is an effective and well-tolerated therapeutic option for patients with refractory non-infectious uveitis, to achieve and maintain disease quiescence.

 Purpose: To assess the efficacy of adalimumab treatment in patients with refractory non-infectious uveitis. Materials and Methods: A retrospective analysis was carried out on patients with chronic non-infectious uveitis treated with adalimumab for longer than 12 months. All patients had active intraocular inflammation and were nonresponsive to other immunosuppressive agents before initiating adalimumab treatment. Results: Twenty-one patients 39 eyes were treated with adalimumab for a mean duration of 26.2  13.2 months. Eleven patients 52.4 remained relapse-free during the treatment. In only one patient 4.8 adalimumab was switched to another drug due to insufficient response. Adalimumab treatment was discontinued in five patients 23.8 after an attack-free period of at least 18 months. Conclusion: Adalimumab is an effective and well-tolerated therapeutic option for patients with refractory non-infectious uveitis, to achieve and maintain disease quiescence.

 Purpose: To assess the efficacy of adalimumab treatment in patients with refractory non-infectious uveitis. Materials and Methods: A retrospective analysis was carried out on patients with chronic non-infectious uveitis treated with adalimumab for longer than 12 months. All patients had active intraocular inflammation and were nonresponsive to other immunosuppressive agents before initiating adalimumab treatment. Results: Twenty-one patients 39 eyes were treated with adalimumab for a mean duration of 26.2  13.2 months. Eleven patients 52.4 remained relapse-free during the treatment. In only one patient 4.8 adalimumab was switched to another drug due to insufficient response. Adalimumab treatment was discontinued in five patients 23.8 after an attack-free period of at least 18 months. Conclusion: Adalimumab is an effective and well-tolerated therapeutic option for patients with refractory non-infectious uveitis, to achieve and maintain disease quiescence.

 Amaç: Enfeksiyöz olmayan dirençli üveit hastalarında adalimumab tedavisinin etkinliğini değerlendirmek. Gereç ve Yöntem: Kronik non-enfeksiyöz üveit tanısıyla 12 aydan uzun süre adalimumab tedavisi alan hastalar retrospektif olarak değerlendirildi. Tüm hastalar adalimumab tedavisine başlamadan önce diğer immünosüpresif ajanlara dirençli olup aktif intraoküler inflamasyon bulgularına sahipti. Bulgular: Yirmi bir hasta 39 göz, ortalama 26.2  13.2 ay süreyle adalimumab tedavisi aldı. Tedavi süresince 11 hastada 52.4 nüks izlenmedi. Sadece bir hastada 4,8 yetersiz yanıt nedeniyle adalimumab tedavisi başka bir ilaç ile değiştirildi. Beş hastada 23.8 en az 18 aylık ataksız dönem sonunda adalimumab tedavisi sonlandırıldı. Sonuç: Adalimumab, dirençli enfeksiyöz olmayan üveit hastalarında remisyonu sağlamak ve sürdürmek için etkili ve iyi tolere edilen bir terapötik seçenektir.

Makale detayları

Adalimumab treatment in adult patients with refractory non-infectious uveitis

Yazarlar:

Ebru Esen | Püren Işık | Selçuk Sızmaz | Nihal Demircan

Yayıncı:

Cukurova University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Cukurova Medical Journal Vol.48 Issue 2, pp.457-462

Belge Tipi:

Makale

Yayın Tarihi:

2/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001286346

pISSN:

2602-3032

Adalimumab

non-infectious uveitis

refractory uveitis

Adalimumab

enfeksiyöz olmayan üveit

dirençli üveit

non-infectious uveitis

refractory uveitis

Sayı

Makale detayları

Yazarlar: Ebru Esen | Püren Işık | Selçuk Sızmaz | Nihal Demircan

Yayıncı: Cukurova University

Ana Başlıklar: Klinik Tıp Bilimleri

Dergi: Cukurova Medical Journal Vol.48 Issue 2, pp.457-462

Belge Tipi: Makale

Yayın Tarihi: 2/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001286346

pISSN: 2602-3032

Sayı

Yazarlar:

Ebru Esen | Püren Işık | Selçuk Sızmaz | Nihal Demircan

Yayıncı:

Cukurova University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Cukurova Medical Journal Vol.48 Issue 2, pp.457-462

Belge Tipi:

Makale

Yayın Tarihi:

2/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001286346

pISSN:

2602-3032